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Metabolism of low density lipoproteins in nephrotic dyslipidemia:
comparison of hypercholesteremia alone and combined hyperlipidemia.
High levels of low-density lipoprotein cholesterol (LDL) (hypercholester-
olemia) are commonly present in the nephrotic syndrome. Another
pattern of dyslipidemia in nephrotic patients is an elevation of both
cholesterol and triglyceride levels (combined hyperlipidemia). It has been
postulated that the underlying cause of nephrotic dyslipidemia is an
hepatic overproduction of apolipoprotein B (apo B)-containing lipopro-
teins. To examine this hypothesis, the metabolism of LDL-apo B was
compared between nephrotic patients with hypercholesterolemia and with
combined hyperlipidemia. Thirteen patients (7 with hypercholesterolemia,
and 6 with combined hyperlipidemia) underwent measurements of turn-
over rates of autologous LDL apo B. The results were compared to
normolipidemic controls and to patients with primary combined hyperlip-
idemia previously studied in our laboratory. Nephrotic patients with
hypercholesterolemia generally had: (a) lower fractional catabolic rates of
LDL apo B than normolipidemic healthy individuals; (b) LDL particles
enriched in cholesterol; but (c) no overproduction of LDL apo B. In
contrast, patients with combined hyperlipidemia were found to have: (a)
high fractional catabolic rates for LDL apo B compared to normolipi-
demic controls; (b) cholesterol-poor LDL particles; and (c) markedly
elevated production rates for LDL. Also, for the group as a whole, there
was a positive correlation between plasma triglyceride levels and fractional
catabolic rates. These data indicate that the metabolism of LDL is
strikingly different between the two forms of nephrotic dyslipidemia.
Although there may be common mechanisms contributing to LDL levels
in nephrotic patients, there also appears to be a divergence of mechanisms
depending on whether hypertriglyceridemia is associated with hypercho-
lesterolemia.
Dyslipidemia is a common feature of the nephrotic syndrome.
Either of two types of dyslipidemia are observed: elevated serum
cholesterol alone (hypercholesterolemia), and simultaneous ele-
vation of serum cholesterol and triglyceride (combined hyperlip-
idemia). Some workers have postulated that the dyslipidemia of
the nephrotic syndrome is caused primarily by increased hepatic
synthesis and secretion of lipoproteins containing apolipoprotein
B [very low density (VLDL) and low density lipoproteins (LDL)]
[1—4]. Also, it has been proposed that hypoalbuminemia induces
the oversynthesis of lipoproteins [5—71. These observations led to
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the lipoprotein "overproduction" hypothesis to explain nephrotic
dyslipidemia. In simple terms, it is commonly believed that
elevation of plasma lipids accompanying the nephrotic syndrome
results from an increased hepatic secretion of apo B-containing
lipoproteins in response to hypoalbuminemia.
More recently, however, this hypothesis has been challenged
along several lines. First, hypercholesterolemia has been observed
in normoalbuminemic patients with nephrotic syndrome, and
treatment of these patients with angiotensin I converting enzyme
inhibitors reduces protein excretion and lowers plasma choles-
terol levels [8]. This finding suggests that proteinuria is more
directly linked to dyslipidemia, and its effect is not necessarily
mediated through hypoalbuminemia. And second, that overpro-
duction of lipoproteins is the major cause of dyslipidemia is open
to question because of the findings of reduced catabolism of apo
B-containing lipoproteins in experimental animals [9—11] and in
some patients [12—14] with the nephrotic syndrome. Thus, two
mechanisms might contribute to nephrotic dyslipidemia: (a) an
overproduction of apo-B containing lipoproteins, and (b) an
impaired catabolism of these lipoproteins. In addition, the reasons
for the occurrence of two different patterns of dyslipidemia—
hypercholesterolemia alone and combined hyperlipidemia—re-
main unexplained. It is apparent then that important issues
remain to be resolved about the mechanisms underlying nephrotic
dyslipidemia.
The current study was designed to determine whether nephrotic
patients with hypercholesterolemia and combined hyperlipidemia
have similar or dissimilar patterns of LDL metabolism. Specifi-
cally, it was asked whether overproduction or decreased clearance
of LDL predominates in each of these two patterns of dyslipi-
demia. In addition, we asked whether other factors (such as
obesity, proteinuria, or hypoalbuminemia), might contribute to
increases in LDL cholesterol that are typical of many patients with
nephrotic dyslipidemia.
Methods
Patients
Thirteen patients (7 women, and 6 men) were recruited for
study from the renal clinics at Parkland Memorial Hospital, and
the Veterans Affairs Medical Center at Dallas, Texas. All subjects
had nephrotic syndrome due to primary glomerular disease. The
time since onset varied from three months to 20 years. Selection
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criteria included proteinuria greater than 3.0 g per day, hypoalbu-
minemia (serum albumin less than or equal to 3.5 g per dl),
creatinine clearance greater than or equal to 30 ml per minute per
1.73 m2, and serum cholesterol greater than 240 mg per dl.
Patients were excluded if they had a history of hypothyroidism or
diabetes mellitus, chronic hepatic disease, hematocrit less than
35%, chronic estrogen, corticosteroid or immunosuppressive ther-
apy, known allergies to iodine or to hypolipidemic drugs. Other
exclusion criteria were family history of hypercholesterolemia and
previous treatment with hypolipidemic agents. Patients selected
for study had a diagnosis of dyslipidemia confirmed by repeated
measurement of serum and triglycerides on two separate occa-
sions. Hypercholesterolemia was defined as a total cholesterol
greater than 240 mg/dl and a total triglyceride less than 250 mg/dl
[15]. Combined hyperlipidemia was defined as a total cholesterol
greater than or equal to 240 mg and triglycerides greater than or
equal to 250 mgldl. Lipid measurements were made after a 12
hour fast, and samples were collected at least one week apart. The
study, a control phase of a drug trial was approved by the
Institutional Review Board at the University of Texas Southwest-
ern Medical Center at Dallas. All subjects gave informed written
consent to participate in the study.
LDL kinetic data from selected control groups of previously
published studies from our laboratory were employed for com-
parison with nephrotic patients [16—18]. The groups consisted of:
(1) 19 young men [mean age 25 1 years, body mass = 102 2%
SEM of desirable weight], (2) 16 middle-aged men [mean age = 55
2 years, body mass index (BMI) = 24.6 1.1 kg/rn2], (3) 13
post-menopausal women (mean age = 57 2 years, BMI = 26.0
0.4 kg/m2), and (4) 11 middle-aged men (mean age = 52 1
years, ideal body mass = 144 2%) with primary combined
hyperlipidemia. The groups of young and middle-aged men, and
postmenopausal women were normolipidemic. The same methods
for study of lipoprotein metabolism were employed in previous
studies and in the current one. All the measurements for the
control groups and the patients with nephrotic syndrome were
made in the same laboratory without a change in procedure.
Diets
The study diet consisted of 40% of total calories as fat (18%
saturates, 17% monounsaturates, and 5% polyunsaturates), 15%
protein, 45% carbohydrate and 400 mg of dietary cholesterol per
day. Dietary counseling was provided by the dietician throughout
the study. Weights of the patients were monitored regularly, and
caloric adjustments were done as needed to maintain a constant
body weight.
Measurement of plasma lipids and lipoprotein cholesterol
Total cholesterol and triglyceride levels in plasma were mea-
sured enzymatically [19, 20]. High-density lipoprotein (HDL)
cholesterol was measured after polyanion precipitation of apo
B-containing lipoproteins with heparin-manganese. LDL-choles-
terol was determined after ultracentrifugal isolation of the frac-
tion d < 1.019 g per ml (VLDL + IDL) from plasma samples, and
determination of cholesterol in the VLDL + intermediate density
lipoprotein (IDL) and the plasma infranatant (d > 1.019 g per
ml). LDL cholesterol was calculated as the difference between
total plasma cholesterol and the sum of VLDL + IDL + HDL
cholesterol [17].
Measurement of the turnover rates of LDL-apo B
Each patient had a plasmapheresis done one week before the
turnover test. The plasma was used to isolate autologous LDL as
detailed previously [211. Briefly, LDL was isolated by preparative
ultracentrifugation at a density of 1.019 to 1.063 g per ml. The
lipoprotein was washed once at its native density, and an aliquot
was dialyzed against 150 m'vi NaCl, 0.01% disodium ethylenedia-
mine tetraacetate (EDTA), pH 7.4. LDL apolipoprotein (2 to 3
mg of protein) was iodinated with 131J using the iodine monochlo-
ride method [21, 22]. Unbound radioactive iodine was removed
from LDL by dialysis. The lipoprotein was mixed with 5% human
serum albumin and unlabeled autologous LDL, millipore filtered
through a 22 tm pyrogen-free filter. The injection mixture was
tested for pyrogens with a limulus test.
The patients were admitted to the General Clinical Research
Center to start the turnover test. Approximately 20 tCi of
autologous 1311-LDL was injected intravenously after a 12 hour
fast. Blood samples were collected at 0, 5, 10, 20, 30, 60, 120, 180,
and 240 minutes after injection, and at 8, 12, 24 hours, followed by
a daily blood drawing for 13 more days. Plasma samples were
aliquoted for counting, and a plot of fraction of injected dose as a
function of time was constructed. This plot was used subsequently
for estimation of the fractional catabolic rates using a two-pool
mammillary model with the Simulation and Modeling Program,
version 30 [23]. Plasma volumes were estimated by isotopic
dilution using the 10 minute sample for these calculations. Levels
of LDL-apo B were measured as detailed below. The pool size of
LDL apo B was calculated as the product of LDL apo B
concentration and plasma volume. Input rates were estimated as
the product of the pool size and the fractional catabolic rate.
Measurement of LDL-apo B concentrations
During the last week of the turnover, additional blood was
drawn on five consecutive days to isolate LDL by preparative
ultracentrifugation [24]. The content of total cholesterol and
apolipoprotein was measured and the ratio of LDL-cholesterol-
to-apolipoprotein was calculated. The absolute concentration of
apo-B was estimated by dividing the absolute concentration of
LDL-cholesterol by the ratio [21].
Renal JInction measurements
Urinary and plasma creatinine were measured by the Jaffe
reaction and urinary protein was measured by the pyrogallol red
method (Smith, Kline Laboratories, Dallas, Texas, USA). Urine
protein excretion rate was normalized for urinary creatinine
excretion and expressed as the ratio of protein to creatinine.
Creatinine clearance was expressed in ml/minll.73 rn2.
Statistical analysis
Data are summarized as means standard deviation. Analysis
of variance (ANOVA) was used to compare control groups to
hypercholesterolemic subjects, and to subjects with combined
hyperlipidemia. Comparisons of parameter means between the
hypercholesterolemic group and subjects with combined hyperlip-
idemia also were done by AND VA. If the Bonferroni equality was
used for multiplicity of testing, a P value (alpha) would be
considered statistically significant at P < 0.05/5 or 0.01 because
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Table 1. Clinical characteristics of patients
Patient
Renal
disease
Age!
gender
years
Body mass
index
kg/rn2
Serum
creatinine
mg/dl
Serum
albumin
g!dl
Creatinine
clearance
mi/mm/I. 73 m2
Urine protein!
creatinine
ratio
Hypercholesterolemia
1
2
3
4
5
6
7
MGN
FS
FS
NIL
FS
MGN
FS
65/F
28/F
48/F
39/F
27/F
68/M
23/M
35.1
30.7
37.2
40.0
35.0
43.2
29.8
1.9
1.7
1.6
0.8
1.4
1.2
1.6
2.7
2.6
3.5
3.4
2.4
2.8
1.8
39
34
73
129
80
61
105
4.1
5.6
1.9
7.0
7.8
5.4
6.7
Mean
SE
43
7
35.9
1.8
1.4
0.1
2.7
0.2
74
13
5.5
0.8
Combined hyperlipidemia
8
9
10
11
12
13
FS
FS
UNK
MGN
MGN
FS
18/F
40/F
61/M
44/M
44/M
21/M
23.1
25.9
31.9
27.6
28.1
22.7
0.7
1.7
2.5
2.3
1.5
1.6
1.0
3
2,5
3.2
2.8
1.0
99
44
41
59
91
66
14.3
2.5
3.8
4.7
6.8
16.0
Mean
SE
38
7
26.6
1.4
1.7
0.3
2.3
0.4
67
10
8.0
2.3
P 0.642 0.002 0.406 0.422 0.642 0.341
Abbreviations are MON, membranous gb merulonephritis; PS, focal sclerosis; NIL, Nil disease; UNK, unknown disease.
five comparisons were made. Finally, Pearson's correlation coef-
ficients were calculated for regression analysis of plasma triglyc-
eride levels versus fractional catabolic rates for LDL after com-
bining the data for both groups: hypercholesterolemia and
combined hyperlipidemia.
Results
Comparison of clinical presentations of the two groups
The clinical characteristics of the patients are compared in
Table 1. Seven patients had hypercholesterolemia, and six had
combined hyperlipidemia. The mean ages for the two groups were
similar. Patients with hypercholesterolemia alone had a higher
average body mass index than those with combined hyperlipid-
emia (P = 0.002; Table 1). There were no differences in levels of
serum creatinine, or albumin between the two groups of patients.
Creatinine clearances and degree of proteinuria were similar in
both groups. Among the hypercholesterolemic group, four pa-
tients (Nos. 2, 3, 5, and 7) had history of focal sclerosis, two (Nos.
1, and 6) had membranous glomerubonephritis, and one (No. 10)
had Nil disease. Among the patients with combined hyperlipid-
emia, three had focal sclerosis, two had membranous glomerulo-
nephritis, and patient No. 10 did not have a renal biopsy to
determine the etiology of the nephrotic syndrome. In addition to
elevated plasma cholesterol and obesity, other risk factors for
coronary artery disease included hypertension (9 patients) and
smoking (one patient). Two patients had history of coronary
artery disease. Patient No. 1 had documented history of myocar-
dial infarction, and patient No. 10 had coronary artery bypass
surgery three years before entering the study. None of the patients
were taking ACE inhibitors. The patients with hypertension were
taking anti-hypertensive medications, but only patient No. 10 was
taking a beta-adrenergic blocker. All patients continued their
baseline medications and health habits during the time of the
study.
Table 2. Plasma total lipids
Patient
Total
cholesterol Triglycerides
HDL
cholesterol
mg!dl
Hypercholesterolemia
1
2
3
4
5
6
7
282
258
280
222
289
286
212
104
192
141
100
79
216
123
50
39
75
60
64
39
47
Mean 261 136 53
Combined hyperlipidemia
8
9
10
11
12
13
458
268
275
404
281
578
1021
390
617
323
733
336
23
33
22
33
27
26
Mean 377 570 27
P 0.037 0.002 0.001
Patients with combined hyperlipidemia had significantly higher
levels of total cholesterol (P < 0.037), and triglyceride (P <
0.002), and lower levels of HDL cholesterol (P < 0.001) than did
the patients with hypercholesterolemia (Table 2). However, there
were no significant differences in the severity of the nephrotic
syndrome between these two groups (Table 1). Although all
patients with hypercholesterolemia had total cholesterol exceed-
ing 240 mg/dl at the time of recruitment, the levels in two patients
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Table 3. Kinetic parameters of LDL apo B
Patient
LDL
cholesterol
LDL
apo B
LDL cholesterol/
apo B
ratio
LDL apo B
pool size
mg
Fractional
catabolic rate
pools/day
LDL apo B
input rate
mg/day/kgmg/dl
Hypercholesterolemia
1
2
3
4
5
6
7
197
187
184
146
202
196
139
107
120
104
73
119
122
72
1.84
1.56
1.77
2.00
1.70
1.61
1.93
3093
3156
2458
3180
4931
4624
2560
0.211
0.332
0.375
0.282
0.254
0.352
0.296
6.5
13.3
12.9
9.3
13.6
15.0
9.6
Mean
SE
179
10
102
8
1.77
0.06
3429
366
0.300
0.022
11.8
1.1
Combined hyperlipidemia
8
9
10
11
12
13
172
178
120
213
111
343
150
116
104
150
98
210
1.15
1.53
1.15
1.42
1.13
1.63
4313
3059
3695
5437
3685
5112
0.978
0.330
0.449
0.429
0.680
0.214
66.0
17.2
21.0
29.0
30.0
20.1
Mean
SE
189
34
138
17
1.34
0.09
4217
374
0.513
0.112
30.5
7.4
P 0.768 0.069 0.002 0 .162 0.069 0.02
(Nos. 4 and 7) were in the range of 200 to 240 mg/dl at the time
of the lipoprotein turnover study (Table 2).
LDL metabolism
Nephrotic hypercholesterolemia vs. nephrotic combined hyperlip-
idemia. This comparison is shown in Table 3. There was no
difference in average LDL-cholesterol levels between the two
groups. However, LDL-apo B levels were somewhat higher in the
group with combined hyperlipidemia. The ratio of LDL-choles-
terol/apo B was lower in those with combined hyperlipidemia,
indicating that they carried less cholesterol per LDL particle than
did patients with hypercholesterolemia. There was a trend to-
wards higher fractional catabolic rates (FCRs) in patients with
combined hyperlipidemia. The input rates of LDL apo B were
definitely higher than in hypercholesterolemia.
Nephrotic hypercholesterolemia versus normolipidemic controls.
Levels of lipids, lipoproteins, and LDL kinetic parameters for
control patients are in Table 4; a statistical comparison of the
parameters with those of the two nephrotic groups are given in
Table 5. Patients with nephrotic hypercholesterolemia had signif-
icantly higher levels of LDL cholesterol (P < 0.0001) than those
of all the control groups (young, middle-aged men, and post-
menopausal women). Levels of apo B also were significantly
higher than young men and postmenopausal women (P < 0.0001).
Further, the ratios of LDL cholesterol-to-apo B were significantly
higher in nephrotic patients than in middle-aged men (P < 0.001)
with a trend for significance for the other groups. Furthermore,
there was a trend towards lower FCRs of LDL apo B in
hypercholesterolemic nephrotic patients compared to control
groups. In contrast, there were no differences in input rates for
LDL apo B between the hypercholesterolemic patients and
controls.
Parameter
Young
men
Middle-
aged men
Post-
menopausal
women
Primary
combined
hyperlipidemia
Number 19 16 13 11
Concentration
mdldl
Total cholesterol 158 7 202 4 211 7 262 4
Triglycerides 88 7 138 2 125 20 492 26
HDL-cholesterol 42 3 38 2 53 3 25 0.3
LDL-cholesterol 108 7 129 4 128 4 130 5
LDLap0B 70±4 91±3 80±2 98±4
LDL-chol/apo B
(ratio) 1.54 0.09 1.42 0.03 1.59 0.04 133 0.03
Kinetic parameters
LDL apo B
fractional
catabolic rate
(pools/day) 0.36 0.02 0.31 0.01 0.35 0.01 0.58 0.02
LDL apo B
input rate
(mg/day/kg) 10.1 0.5 12.8 0.5 11.1 0.6 22.0 0.6
Nephrotic combined hyperlipidemia versus controls. Levels of
LDL cholesterol and LDL apo B were significantly higher (P <
0.001) in nephrotic patients with combined hyperlipidemia com-
pared to normolipidemic controls and to patients with primary
combined hyperlipidemia. The ratios of LDL cholesterol-to-apo B
tended to be lower in the nephrotic patients than in normolipi-
demic controls, but not compared to patients with primary
combined hyperlipidemia. Further, FCRs for LDL apo B were
significantly higher (P < 0.001) in nephrotic patients than in
normolipidemic controls, but FCRs were similar to those in
Table 4. Levels of plasma lipids, lipoproteins, and LDL kinetics of
control groups
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Table 5. Alpha values for analysis of variance
Plasma triglycerides, mg/dI
concluded that increased production of LDL was mainly respon-
sible for the hypercholesterolemia. Still, careful examination of
their data reveals that input rates were not markedly elevated, and
some of their patients also had reduced fractional clearance for
LDL. Warwick et al [12, 14, 28] in three different reports indicated
a dual mechanism for nephrotic hypercholesterolemia; some of
their patients had overproduction of LDL, whereas others had a
delayed clearance of LDL. An important point to make is that in
these studies no attempt was made to correlate the metabolism of
LDL with triglyceride levels, that is, patients with normotriglyc-
eridemia and hypertriglyceridemia were not distinguished. Our
previous studies [29—31] in patients with primary hypertriglyceri-
demia, however, have shown that LDL kinetics differ markedly
depending on whether triglyceride levels are elevated. For this
reason, the current study was designed to compare and contrast
turnover rates of LDL in nephrotic patients with hypercholester-
olemia and those with combined hyperlipidemia.
Hypercholesterolemia
In the current patients diagnosed as hypercholesterolemic,
LDL-cholesterol levels were significantly higher than all control
groups. Three mechanisms might account for increased LDL-
cholesterol concentrations: overproduction of LDL particles, de-
fective clearance of LDL, and an enhanced cholesterol content of
LDL particles. Either of the former should be accompanied by
increased LDL-apo B concentrations. Indeed, a high LDL-apo B
level was present in the nephrotic patients which implicated one
or the other, or both, of the first two mechanisms. Input rates for
LDL-apo B were not found to be significantly higher in nephrotic
patients compared to controls. However, input data for hypercho-
lesterolemic subjects were normalized for total body weight, and
since our nephrotic patients in this category were on the average
more obese than controls, absolute input rates for LDL may have
been somewhat higher in the nephrotic patients than in controls.
Previous investigations [32, 33] have shown that obesity itself
increases absolute input rates for LDL-apo B, but when input
rates are normalized for total body weight, values are similar to
those of normal-weight subjects. Therefore, if the nephrotic
Hypercholesterolemia
vs. vs.
vs. Middle- vs. Primary
Young aged Postmenopausal combined
men men women hyperlipidemia
LDL-cholesterol 0.0001 0.0001 0.0001 0.0001
LDL apo B 0,0001 >0.1 0.0002 >0.1
LDL-cholesterol/
apo B 0.0334 0.0001 0.0977 0.0001
LDL apo B FCR 0.0347 >0.1 0.0977 0.0001
LDL apo B
input rate >0.1 >0.1 >0.1 0.0001
vs.
Young
men
Combined hyperlipidemia
vs. vs.
Middle- vs. Primary
aged Postmenopausal combined
men women hyperlipidemia
LDL-cholesterol 0.0001 0.0001 0.0001 0.0001
LDL apo B 0.0001 0.0001 0.0001 0.0001
LDL-cholesterol/
apo B 0.0977 0,0977 0.0977 >0.1
LDL-apo B FCR 0,0001 0.0001 0.0001 >0.1
LDL apo B
input rate 0.0001 0.0001 0.0001 0.0001
1.00
0.75
CS LC.) J Q)
.2 0 0
cs 0.25LL'
0.00
Fig. 1. Plot of fractional catabolic rate (pools per day) of LDL apo B as a
function of plasma triglyceride concentrations (mg/dl). The linear regression
analysis of plasma triglyceride levels vs. fractional catabolic rate of LDL
apo B for all of the thirteen patients with nephrotic syndrome showed a
significantly high correlation.
0 400 800 1200
patients with primary combined hyperlipidemia. LDL-apo B input
rates in the groups with nephrotic combined hyperlipidemia were
significantly higher (P < 0.001) than in both normolipidemic
controls and patients with primary combined hyperlipidemia.
Relation of plasma triglycerides to fractional catabolic rate of
LDL. The levels of plasma triglyceride correlated positively with
the fractional catabolic rate of LDL for all patients (N = 13; Fig.
1). The correlation coefficient was 0.90, P = 0.0001. Three
patients (Nos. 8, 10, 12) with combined hyperlipidemia had
triglyceride levels above 600 mg/dl, and they also had the highest
FCRs for LDL.
Discussion
For many years it has been postulated that the primary mech-
anism for hyperlipidemia in the nephrotic syndrome is an hepatic
overproduction of apo B-containing lipoproteins. Studies in lab-
oratory animals [9—11] and in tissue culture [5, 6] have suggested
that low levels of serum albumin (or oncotic pressure) lead to
increased secretion of lipoproteins by liver cells. In more recent
years however, there is some evidence from animal studies
showing that other mechanisms may contribute to the dyslipi-
demia of the nephrotic syndrome [9, 10, 25—27].
A limited number of investigations on the metabolism of apo
B-containing lipoproteins have been carried out in human pa-
tients with nephrotic syndrome in the attempt to determine the
causes of hyperlipidemia. Primary emphasis has been given to
understanding causes of hypercholesterolemia (elevated LDL
cholesterol). In several previous reports [12—14, 28], mixed pat-
terns of LDL-apo B metabolism have been observed in nephrotic
patients with hypercholesterolemia, and no single pattern has
emerged as being predominant. For example, Vega and Grundy
[21] reported that some nephrotic patients had an increased input
(overproduction) of LDL, whereas other patients had a reduced
clearance of this lipoprotein. In another study, Joven et a! [13]
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syndrome had independently, raised input rates for LDL-apo B,
values should have been elevated after normalization for body
weight. Since such an increase was not found, it seems unlikely
that the nephrotic syndrome per se contributed importantly to any
enhanced input of LDL apo B in our hypercholesterolemic
patients.
In contrast, fractional clearance of LDL apo B tended to be
lower than in controls, especially as compared to young adult men
and postmenopausal women. This finding suggests the presence of
a relative defect in clearance of LDL apo B. If so, patients with the
nephrotic syndrome may have had some down-regulation of
LDL-receptor activity. This effect could be secondary to an
increased synthesis of cholesterol, which has been reported in
animals with experimental nephrosis [26, 27].
Another feature of LDL metabolism in our hypercholester-
olemic patients was the presence of LDL particles that were
overly enriched with cholesterol. LDL-cholesterol/apo B ratios
averaged higher than those of control patients. Since each LDL
particle contains only one molecule of apo B, an increase in the
cholesterol/apo B ratio signifies an abnormally high cholesterol
content of individual LDL particles. Our data indicate that a high
LDL-cholesterollapo B ratio contributed importantly to the hy-
percholesterolemia in many of nephrotic patients. The mechanism
for this high ratio is not entirely clear. Those patients having
higher ratios tended to have lower FCRs for LDL; consequently,
a delay in clearance of LDL may have allowed more time for
cholesterol ester transfer protein (CETP) to transfer more cho-
lesterol ester to LDL particles. In addition, it has been reported
that plasma levels of CETP are high in nephrotic patients [34, 35].
An elevation of CETP could cause still more enrichment of LDL
particles with cholesterol esters. Thus, in our nephrotic patients
having only hypercholesterolemia, a relatively low fractional clear-
ance rate for LDL plus cholesterol enrichment of LDL particles
appeared to contribute more to high LDL-cholesterol levels than
did overproduction of LDL particles.
Combined hyperlipidemia
This condition denotes increased concentrations of both cho-
lesterol and triglycerides. The nephrotic syndrome classically is
characterized by hypercholesterolemia, but elevated triglycerides
commonly are present as well. The mechanisms responsible for
high triglyceride levels are not well understood. However, we
previously reported that hypertriglyceridemia in nephrotic hu-
mans is due mainly to defective catabolism of VLDL triglycerides
[21]. This finding has been confirmed by Warwick et al [14]. From
studies in rats, Davies et al [9] proposed that urinary loss of a
liporegulatory substance in the urine, independent of albumin,
causes defective clearance of triglyceride-rich lipoproteins. Fu-
rukawa et al [10] likewise reported that experimental nephrosis in
rats is associated with defective catabolism of VLDL triglycerides;
this defect appeared to be due to resistance of VLDL to the action
of lipoprotein lipase. Apo C-lI, which is known to activate
lipoprotein lipase, is lost in the urine of nephrotic patients [36],
but since only small amounts are required for apo C-II's cofactor
action, this mechanism probably does not explain the decreased
catabolism of triglyceride-rich lipoproteins. Other factors there-
fore appear to be responsible.
Our patients with the nephrotic syndrome and combined hy-
perlipidemia, like those with hypercholesterolemia, had high
levels of LDL cholesterol and LDL apo B. However, in contrast to
the hypercholesterolemic patients, those with combined hyperlip-
idemia had strikingly elevated input rates for LDL apo B. An
increased input of LDL apo B is consistent with studies in
experimental animals in which an increased secretion of apo
B-containing lipoproteins has been identified [1—3]. Nonetheless
an alternate mechanism for a high input of LDL apo B can be
envisioned. This is a reduced uptake of LDL precursors (VLDL
and IDL) by the liver. By this mechanism, more of these LDL
precursors would have the chance to be converted to LDL. Our
kinetic studies do not directly differentiate between the alternative
explanations for a high input of LDL apo B, but an important clue
to a mechanism may be forthcoming by examining FCRs for LDL.
The nephrotic patients with combined hyperlipidemia had
relatively high FCRs for LDL apo B. Theoretically, an increased
hepatic secretion of apo B-containing lipoproteins would not be
expected to produce the high FCRs for LDL observed in our
patients. Instead, hepatic overproduction of lipoproteins should
cause "overloading" of receptor-mediated clearance of lipopro-
teins, including LDL receptors, by LDL precursors; if so, FCRs
for LDL should be relatively low. Instead, our patients with the
highest input rates for LDL apo B generally had the highest FCRs
for LDL. Since this response was the opposite of what would be
expected from hepatic overproduction of apo B-containing li-
poproteins, it seems unlikely that the high inputs of LDL can be
explained primarily by this mechanism.
As indicated above, another mechanism for increased input
into the LDL-apo B compartment could be a reduced hepatic
intake of LDL precursors by the liver. In this case, more of these
precursors (VLDL and IDL) would be converted to LDL. Since
fewer precursors would be removed by the liver, more hepatic
LDL receptors should be available for uptake of LDL, and hence,
FCRs for LDL would be higher. This could account for the
relatively high FCRs for LDL observed in nephrotic patients with
combined hyperlipidemia. In fact, the fewer the number of LDL
precursors removed by LDL receptors, the greater would be the
number of lipoprotein particles converted to LDL and the higher
would be FCRs for LDL. This pattern in fact was observed in our
patients, and the phenomenon supports this mechanism as an
explanation for their high input rates for LDL. Previous studies
have shown a similar pattern of LDL kinetics in patients with
primary hypertriglyceridemia, as well as in those with primary
combined hyperlipidemia (Table 4). There appears to be some-
thing about the hypertriglyceridemic state that favors the conver-
sion of LDL precursors to LDL, rather than direct uptake of these
precursors by the liver. The precise mechanisms for this redistri-
bution of fates of LDL precursors are unclear.
An important question is whether a redistribution in catabolic
pathways for LDL precursors contributes to higher LDL-apo B
levels. Certainly, there is an increased input of LDL apo B that
should raise the levels. On the other hand, more LDL receptors
are left unused by precursors and thus are available for LDL
uptake. Consequently, the high FCRs for LDL could correct the
imbalance in LDL levels caused by an increased input rate for
LDL apo B. This appears to be the case for many patients with
primary hypertriglyceridemia who do not have elevated LDL-apo
B concentrations [29—31]. Thus, inspite of relatively high FCRs
for LDL, the high LDL apo-B levels in patients with combined
hyperlipidemia of the nephrotic syndrome still could be the result
of a decrease in the expression of LDL receptors, with perhaps a
contribution from increased hepatic secretion of apo B-containing
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lipoproteins. Nonetheless, it is clear that the kinetics of LDL-apo
B are quite different between the two forms of nephrotic dyslipi-
demia: hypercholesterolemia and combined hyperlipidemia. It
also is apparent that kinetic data from these two forms of
dyslipidemia should not be combined in any attempt to under-
stand the mechanisms of elevated LDL-apo B concentrations in
the nephrotic syndrome.
Conclusions
This study shows that LDL-apo B kinetics are strikingly differ-
ent between nephrotic patients with hypercholesterolemia alone
and those with combined hyperlipidemia. However, both forms
are characterized by high levels of LDL apo B and LDL choles-
terol. In patients with hypercholesterolemia, elevated LDL apo B
concentrations appear to be due more to a decrease in fractional
clearance of LDL apo B than to an overproduction of LDL
particles. In these patients LDL-cholesterol levels are further
enhanced by increases in LDL-cholesterol/apo B ratios. Patients
with combined hyperlipidemia also have high levels of LDL apo
B, but in contrast to those with hypercholesterolemia, LDL-
cholesterol/apo B ratios tend to be low. Thus, in patients with
combined hyperlipidemia, LDL-apo B concentrations usually are
disproportionately high, compared to LDL-cholesterol levels,
whereas the opposite is true for those with hypercholesterolemia.
Another striking difference between the two forms of dyslipidemia
is that input rates for LDL apo B are high in patients with
combined hyperlipidemia, and yet, LDL-apo B levels remain only
moderately elevated because of corresponding high FCRs for
LDL. Since high input rates and high FCRs for LDL appear to be
linked in these patients, it is not certain that the former are
primarily responsible for the high LDL apo B levels. Instead, it is
certainly possible that a reduced expression of LDL receptors still
contributes to elevated LDL apo B in these patients. We must
note that some degree of enhanced hepatic secretion of apo
B-containing lipoproteins, as reported in some animal models,
could not be excluded by our isotopic methods. However, the
present study points to additional mechanisms besides overpro-
duction of apo B-containing lipoproteins for augmenting LDL-
apo B and LDL-cholesterol levels in the nephrotic syndrome, and
these other mechanisms need further investigation.
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